Intensity Therapeutics Secures $6.6 Million to Advance Cancer Treatment Innovations

Intensity Therapeutics, a biotechnology company at the forefront of developing innovative intratumoral cancer therapies, has successfully raised $6.6 million in gross proceeds through an At-the-Market (ATM) offering. This financial boost enables the company to further its clinical trials into the latter half of 2026, focusing on treatments designed to directly kill tumors and enhance the immune system's ability to recognize cancers.

The ATM offering, which involved the sale of 19,868,658 shares at an average price of $0.3323 per share, not only strengthens Intensity Therapeutics' balance sheet but also reflects investor confidence in the company's proprietary non-covalent conjugation technology. Lewis H. Bender, President and CEO of Intensity, highlighted the strategic advantage of the ATM sales, noting the favorable pricing and lower capital-raising costs compared to previous offerings.

At the core of Intensity Therapeutics' research is INT230-6, a lead investigational product candidate developed using the company's DfuseRx℠ technology platform. INT230-6 combines two potent anti-cancer agents with a diffusion enhancer, designed for direct intratumoral injection to maximize tumor saturation and minimize systemic side effects. This approach not only aims for local disease control but also triggers an immune response against the cancer, offering a promising avenue for treating malignancies resistant to conventional therapies.

Intensity Therapeutics has already made significant strides in clinical research, with over 200 patients enrolled across multiple studies, including Phase 1/2 and Phase 2 trials for metastatic cancers and locally advanced breast cancer, respectively. The company has also initiated a Phase 3 trial in soft tissue sarcoma and a Phase 2 study in collaboration with the Swiss Cancer Group, focusing on triple-negative breast cancer. These efforts underscore the potential of INT230-6 to revolutionize cancer treatment by turning deadly cancers into manageable conditions.

For more information on Intensity Therapeutics and its groundbreaking work in cancer therapy, visit https://www.intensitytherapeutics.com.